The state’s Department of Health and Human Services this week sent letters to firms that did not provide required information about production costs, marketing and advertising costs, patient assistance programs, wholesale acquisition costs, and historical increases, among other information.
Last week, Nevada told 21 diabetes drug manufacturers the state wants $17.4 million in penalties for noncompliance with a new price transparency law.
According to press reports, the state’s Department of Health and Human Services this week sent letters to firms that did not provide required information about production costs, marketing and advertising costs, patient assistance programs, wholesale acquisition costs, and historical increases, among other information.
Thirteen companies were assessed $910,000, followed by Daiichi Sankyo, which was assessed a $735,000, which was the smallest penalty.
According to a state drug transparency report released earlier this year, about 12.6% of adults in Nevada have diabetes, and 1 in 4 don’t know that they have the disease. Direct and indirect diabetes related expenses cost $2.7 billion in the state.
The transparency law requires that manufacturers divulge justifications for price increases; the most cited reason research and development investments, followed by claims that the drug has more competitive value, changes in marketplace dynamics, rebates provided to pharmacy benefit managers (PBMs), insurers, and others, and manufacturing investments.
The Nevada law requires that PBM managers report rebates in aggregate (but not for individual drugs).
A recent study said these laws are largely ineffective at revealing true transaction prices for drugs, though policy makers have hailed these legislative solutions as steps toward bringing down the high cost of drugs for US patients. The laws do not require the release of real price information, including discounts and rebates, by all players in the supply chain.
The Nevada Independent, a nonprofit news organization, reported that the companies have 30 days to either pay the fines in full or 10 days to request an informal dispute resolution meeting with the state. If the companies don’t respond at all, the department will refer the cases to the attorney general’s office to seek a court order to collect the penalty.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.